ulinastatin: Low dose:100000 IU iv tid×5d; High dose:300000 IU iv tid×5d, diluted in 100mL normal saline
Normal Saline (0.9% NaCl): Equal-volume 0.9% normal saline iv tid×5d as placebo
Study summary
Complicated intra-abdominal infection (cIAI) triggers dysregulated systemic inflammation and immune paralysis leading to high organ failure and death risk. Ulinastatin is a protease inhibitor with anti-inflammatory properties, but its dose-related effects on immune-inflammation of cIAI patients remain unclear. This single-center single-blinded three-arm randomized controlled pilot study enrolls adult cIAI patients (≥18 years, SOFA≥2) at Fujian Medical University Union Hospital. Eligible patients are randomized into low-dose ulinastatin, high-dose ulinastatin and normal saline placebo groups (1:1:1, 5 days intravenous treatment plus standard care), total planned enrollment 165 participants after 10% dropout adjustment. Primary endpoint is Day5 change of Systemic Immune-Inflammation Index (SII); secondary outcomes include serial inflammatory biomarkers, SOFA variation, organ dysfunction, hospitalization duration, 28-day mortality and safety profiles. This pilot aims to clarify ulinastatin's immune-modulating effect and inform future large RCT design.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Able to provide written informed consent voluntarily.
2. Age ≥ 18 years old, any gender.
3. Diagnosed with severe complicated intra-abdominal infection (cIAI) within 48 hours, consistent with the 2025 expert consensus for cIAI diagnosis. Diagnosis is confirmed by clinical symptoms (fever, abdominal pain, distension, etc.), abdominal imaging (CT/ultrasound/MRI), intraoperative findings, or positive pathogen culture of abdominal drainage fluid.
4. Baseline Sequential Organ Failure Assessment (SOFA) score ≥ 2 points.
Exclusion Criteria:
1. Severe immune deficiency conditions, including AIDS, prior solid organ or bone marrow transplantation, HIV infection with CD4 count \< 200 cells/mm³, long-term high-dose glucocorticoid therapy (prednisone \> 20 mg/day), ongoing chemotherapy for malignant tumors, or absolute neutrophil count \< 1000 cells/mm³.
2. Severe irreversible underlying diseases, including chronic renal failure requiring dialysis, Child-Pugh grade C liver disease, liver disease with severe portal hypertension, or acute liver failure.
3. Patients with active malignant tumors, pregnancy, or severe psychiatric disorders.
4. American Society of Anesthesiologists (ASA) physical status grade IV or above.
5. Severe coagulation disorder defined as ISTH-DIC score ≥ 5 points.
6. Critically ill patients with expected death within 48 hours after admission.
7. Known allergy to ulinastatin or any ingredients of the study preparation.
8. Any condition that, in the judgment of the principal investigator, makes the patient inappropriate for trial participation.
Primary outcome measure(s)
Mean change from baseline in Systemic Immune-Inflammation Index (SII) at Day 5 — Baseline (before treatment), Day 5 The Systemic Immune-Inflammation Index (SII) is calculated from routine blood test results as platelet count multiplied by neutrophil count divided by lymphocyte count. The mean change in SII values from baseline to Day 5 will be compared across the three groups to assess the immunomodulatory effect of ulinastatin on systemic immune-inflammatory status in patients with complicated intra-abdominal infection.
Trial sites (1)
Facility
City
Region
Status
Fujian Medical University Union Hospital
Fuzhou
Fujian
More Fujian Medical University Union Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.